Mercado Global de Doxorrubicina Lipossomal – Tendências da Indústria e Previsão para 2030

Análise e dimensão do mercado de doxorrubicina lipossomal

A doxorrubicina lipossomal é muito procurada devido à sua aplicação no tratamento do cancro, sarcoma de Kaposi e várias outras doenças. Prevê-se que as vendas de doxorrubicina lipossomal cresçam após o mau funcionamento do tratamento sistémico anterior para o cancro dos ovários e outros sarcomas de Kaposi relacionados com a SIDA. O tamanho do mercado está a aumentar à medida que as pessoas se tornam mais conscientes das inúmeras opções de tratamento do cancro. As inovações permitem a entrega de medicamentos em locais específicos e a libertação regulada de medicamentos no organismo.

A Data Bridge Market Research analisa uma taxa de crescimento no mercado de doxorrubicina lipossomal no período de previsão 2023-2030. O CAGR esperado do mercado da doxorrubicina lipossomal tende a rondar os 5,90% no período de previsão mencionado. O mercado foi avaliado em 1.240 milhões de dólares em 2022 e cresceria até 1.961,50 milhões de dólares até 2030. Para além dos insights sobre os cenários de mercado, como o valor de mercado, a taxa de crescimento, a segmentação, a cobertura geográfica e os grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research inclui também análise especializada aprofundada, epidemiologia de doentes, análise de pipeline, análise de preços e estrutura regulamentar.

Âmbito e segmentação do mercado da doxorrubicina lipossomal

Market Definition

Doxorubicin (liposomal) is used to treat breast cancer, AIDS related Kaposi sarcoma, ovarian cancer and other cancerous tumours. Doxorubicin is an anti-cancer chemotherapy drug encapsulated in a closed lipid sphere called liposome. This medicine is classified as an "anthracycline antibiotic." It is given by injection through a vein (intravenously, by IV). Doxorubicin (liposomal) is an irritant. 

Global Liposomal doxorubicin Market Dynamics

Drivers

• Increased Awareness About Cancer Therapies

Numerous government programs aimed at raising awareness and providing new cancer therapy methods have increased the demand for liposomal doxorubicin and are likely to increase more during the forecast period. For instance, in 2020, the National Comprehensive Cancer Control Program, that provides guidance, funding, and technical assistance to help programs in implementing cancer prevention and control plans, may surge the market opportunities for major market players to launch new products into the market

• Rising Prevalence of Breast Cancer

According to the International Agency for Research on Cancer (IARC) in December 2020, 1 in 4 cancer diagnoses in women globally is breast cancer cases. As per the records of WHO, there were around 2.3 million women diagnosed with breast cancer in the year 2020, and there were almost 685,000 deaths worldwide. Breast cancer was the most common cancer in the world in 2020, with 7.8 million women having received a diagnosis in the last five years. Thus, this prevalence is demanding more growth of these drugs.

Opportunities

• Increasing Demand of J&J (Doxil/Caelyx)

J&J (Doxil/Caelyx) is helping in increasing the market growth. The high occurrence and mortality rate of ovarian cancer is one of the vital factors for this market. The increasing demand for Doxil or Caelyx as a second-line treatment for ovarian carcinoma is also projected to boost the demand in the coming few years. Thus, it boost the growth of the market.  

• Increasing Product Launches

The launch of several products are creating much opportunities for the market growth. The increasing availability of products such as Nudoxa injections, Evacet, and DOXT SL tablets in the European region, is one of the essential factors driving the demand during the forecast period. Furthermore, the existence of numerous pipeline products that are awaiting approval by the U.S. FDA and European Medicines Agency is one of the major attributes of this market.

Restraints/Challenges

• High Cost of Treatment Processes

The cost of treatment and the medications essential to reduce the tumor growth is extremely expensive. There are numerous drugs and injections that are of very high cost which in turn are hampering the growth of the market.

This liposomal doxorubicin market  report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the liposomal doxorubicin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Liposomal Doxorubicin Market       

The liposomal doxorubicin market were greatly affected as the COVID-19 pandemic caused havoc on healthcare systems globally, causing routine care to be disrupted in many hospitals and exposing cancer patients to extensive dangers. In 2021, according to a study titled "Impact of COVID-19 on cancer care in India: a cohort study," in which the researchers collected data on new patient registrations, hospital admissions, outpatient clinic visits, daycare admissions for chemotherapy, minor and major surgeries, patients receiving radiotherapy, and diagnostic tests. They found that the number of new patients registered reduced from 112 270 to 51 760. The data suggests that the demand for liposomal doxorubicin diminished due to COVID-19. The sales of also decreased as the patient's follow-up visits, hospital admissions, and outpatient chemotherapy was reduced due to COVID-19.

Global Liposomal Doxorubicin Market Scope

The liposomal doxorubicin market is segmented on the basis of product, type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Formulation

• Lyophilized Powder
• Doxorubicin Injection

Application

• Bladder Cancer
• Kaposi Sarcoma
• Leukemia
• Lymphoma
• Breast Cancer
• Others

Product

•  Doxil
•  Lipodox
• Myocet
• Others

Type

• Anthracycline Antibiotic
• Others

Route of Administration

• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Liposomal Doxorubicin Market Regional Analysis/Insights

The liposomal doxorubicin market is analyzed and market size insights and trends are provided by product , type, route of administration, end-user, distribution channel as referenced above.

Os principais países abrangidos no relatório de mercado da doxorrubicina lipossomal  são os EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão , Índia, Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito , Israel, Resto do Médio Leste e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul.

Espera-se que a América do Norte tenha o maior crescimento do mercado devido às crescentes ocorrências de sarcomas, cancro da mama, do ovário e outros cancros.

A Ásia-Pacífico domina o mercado devido aos elevados gastos no setor da saúde e aos crescentes avanços tecnológicos no mercado.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, o impacto das tarifas nacionais e das rotas comerciais, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.   

Cenário competitivo e análise global da quota de mercado da doxorrubicina lipossomal

O panorama competitivo do mercado da doxorrubicina lipossomal fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado da doxorrubicina lipossomal.

Os principais players que trabalham no mercado da doxorrubicina lipossomal incluem:

• (EUA)
• Sun Pharmaceutical Industries Ltd. (Índia)
• Merck & Co., Inc.
• Cipla Inc. (Índia)
• Lupin (Índia)
• Cadila Pharmaceuticals (Índia)
• SRS Life Sciences (Índia)
• Shanghai Fudan-zhangjiang Biopharmaceuticals Co., Ltd (China)

SKU-57255